
Certain patients with lung cancer who have EGFR exon 20 insertion mutations may have a new treatment option, which welcomes a new “milestone.”
Ashley Chan, assistant editor for CURE®, has been with MJH Life Sciences since June 2023. She graduated with a B.A. in Communication Studies from Rowan University. Outside of work, Ashley enjoys spending time with family and friends, reading new novels by Asian American authors, and working on the manuscript of her New Adult novel.
Certain patients with lung cancer who have EGFR exon 20 insertion mutations may have a new treatment option, which welcomes a new “milestone.”
An expert spoke with CURE® about the next steps for patients recently diagnosed with prostate cancer and the types of treatments they may receive.
A patient received a dose of the novel menin inhibitor, ziftomenib, plus Xospata in a phase 1 trial for patients with AML.
Attending follow-up appointments as blood cancer survivors can help prevent more dangerous outcomes, including secondary cancers, an expert told CURE®.
From Jason Kelce honoring the team trainer who has been diagnosed with cancer to deaths in the sports reporting and music world, here’s what’s happening in the oncology space this week.
Survivors of rhabdomyosarcoma may be at higher risk for poorer psychological outcomes, that radiation therapy and smoking may worsen.
In some patients with rare cancers, certain strains of gut bacteria could boost responses to immunotherapy combinations, researchers established.
We asked our audience of patients and survivors about their thoughts on the use of cannabis during cancer. Here’s what they had to say.
The skin microbiomes of patients with breast cancer who received radiation therapy may affect whether they get radiation dermatitis, a study showed.
Researchers on a phase 1b/2 trial dosed their first patient with samuraciclib and ARV-471, a novel treatment regimen for patients with a breast cancer subset.
A phase 2 trial showed that Trodelvy plus Keytruda had a high response rate with lasting responses, emphasizing “potential additive or synergistic effects,” an expert said.
Sociodemographic factors affect some survivors who may not have easy access to health care or healthy food, reducing their health-related quality of life.
Mental health after cancer treatment has not been talked about enough, experts say, so how should survivors effectively care for their minds?
Researchers on a phase 1/2 trial provided the first dose of gotistobart plus Pluvicto to a specific patient population with prostate cancer.
Prescribing newly FDA-approved drugs may take a long time before patients can start taking them, so experts told CURE® why.
Keytruda plus chemotherapy has been granted a priority review by the FDA to treat certain patients with endometrial cancer.
A patient in a phase 2 trial has received the first dose of a novel combination of botensilimab and balstilimab plus agenT-979, an allogeneic cell therapy.
Patients who received breast-conserving surgery may face a higher risk for reoperation and higher health care costs, research showed.
An immunotherapy-targeted therapy combination could offer a new treatment option to patients with non-small cell lung cancer whose tumors have become resistant to other treatments.
Treatment with immunotherapy demonstrated positive results regarding survival in patients with two types of soft-tissue sarcomas, research found.
Survivors who were more physically active may experience less pain than survivors who were not as physically active, research found.
Patients with MPNs who are JAK2V617F- and CALR-positive had different bacterial compositions compared with people without MPNs, research found.
The novel drug BMX-001 showed improved survival in certain patients with high-grade glioma and reduced cognitive decline caused by radiation therapy.
Newly diagnosed patients with FLT3-mutated acute myeloid leukemia showed improvements after receiving crenolanib plus chemotherapy in a recent study.
A digital tool for caregivers of patients with cancer in hospice care significantly reduced some of the caregiver burden while improving their mood.
Patients with relapsed or refractory multiple myeloma had lower progressive disease outcomes when receiving Blenrep with Velcade and dexamethasone, research found.
Treatment for muscle-invasive bladder cancer called dose-dense MVAC did not improve survival compared with chemotherapy alone, although one drug in the combination faces a shortage.
Substance use disorders, such as alcohol use disorder, were found to be more prevalent among survivors of specific cancer types, according to research.
As a survivor, Karen Gartland found that a mind-body program was helpful, as it taught her useful techniques for when her health anxiety spikes.
Patients with advanced synovial sarcoma may have a new therapy option if the novel drug, afami-cel, is approved by the FDA after the priority review.